Cargando…
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study
Autores principales: | Lora-Tamayo, Jaime, Maestro, Guillermo, Lalueza, Antonio, Rubio-Rivas, Manuel, Villarreal Paul, Gracia, Arnalich Fernández, Francisco, Beato Pérez, José Luis, Vargas Núñez, Juan Antonio, Llorente Barrio, Mónica, Lumbreras Bermejo, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877892/ https://www.ncbi.nlm.nih.gov/pubmed/33582204 http://dx.doi.org/10.1016/j.jinf.2021.02.011 |
Ejemplares similares
-
Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010) -
Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020) -
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023) -
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
por: Mas Serrano, Miguel, et al.
Publicado: (2020)